Home › AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients
 

Keywords :   


AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow Transplant Patients

2014-05-08 15:00:00| Merck.com - Research & Development News

Dateline City: WUPPERTAL, Germany & WHITEHOUSE STATION, N.J. WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orInvestors:Carol Ferguson, 908-423-4465orAiCurisMedia:Katja Woestenhemke, +49-202-317-63-1176 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results publication journal agent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.06Eastern North Pacific Tropical Weather Outlook
27.06Atlantic Tropical Weather Outlook
27.06Texas & Southwestern Cattle Raisers Association concludes 2024 summer meeting
27.06CCA secures funding for wolf compensation in revised budget
27.06Kimberly-Clark Could Close U.K. Plant
27.06MU Extension to host 3 feedlot educational events this summer
27.06Whats your marketing plan for beef-on-dairy calves?
27.06Sunn hemp can boost summer pastures
More »